The first 2 authors contributed equally to this article.
Article first published online: 15 NOV 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 14, pages 3579–3586, 15 July 2012
How to Cite
Lee, J. K., Park, H. S., Kim, D.-W., Kulig, K., Kim, T. M., Lee, S.-H., Jeon, Y.-K., Chung, D. H., Heo, D. S., Kim, W.-H. and Bang, Y.-J. (2012), Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer, 118: 3579–3586. doi: 10.1002/cncr.26668
Presented in part at the metastatic/nonsmall cell lung cancer poster discussion session of 47th Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2011; Chicago, IL.
- Issue published online: 2 JUL 2012
- Article first published online: 15 NOV 2011
- Manuscript Accepted: 5 OCT 2011
- Manuscript Revised: 3 OCT 2011
- Manuscript Received: 25 AUG 2011
- anaplastic lymphoma kinase;
- epidermal growth factor receptor;
- nonsmall cell lung carcinoma;
- overall survival;
- tyrosine kinase inhibitor
The purpose of this study was to investigate the overall survival (OS) of patients with advanced ALK-positive nonsmall cell lung cancer (NSCLC) who were managed in the pre-ALK inhibitor era and to compare their survival with that of a matched case cohort of ALK wild-type (WT) patients.
Data from 1166 patients who had stage IIIB/IV NSCLC with nonsquamous histology were collected from the NSCLC database of Seoul National University Hospital between 2003 and 2009. ALK fluorescence in situ hybridization (FISH) was used to analyze 262 patients who either had the WT epidermal growth factor receptor (EGFR) or were nonresponders to previous EGFR tyrosine kinase inhibitor (TKI) therapy. Overall survival (OS) was compared between 3 groups: 1) ALK-positive patients, 2) EGFR mutation-positive patients, and 3) ALK-WT/EGFR-WT patients. Progression-free survival (PFS) after first-line chemotherapy and EGFR TKIs also was analyzed.
Twenty-three patients were ALK-positive according to FISH analysis and did not receive ALK inhibitors during follow-up. The median OS for ALK-positive patients, EGFR mutation-positive patients, and WT/WT patients was 12.2 months, 29.6 months, and 19.3 months, respectively (vs EGFR mutation-positive patients, P = .001; vs WT/WT, P = .127). The PFS after first-line chemotherapy for the 3 groups was not different. However, the PFS for patients who received EGFR TKIs was shorter in ALK-positive patients compared with the other 2 groups (vs EGFR mutation-positive patients, P < .001; vs WT/WT, P < .021).
In the pre-ALK inhibitor era, ALK-positive patients experienced the shortest survival, although it did not differ statistically from that of WT/WT patients. Although their responses to platinum-based chemotherapy were not different from comparator groups, ALK-positive patients were even more resistant to EGFR TKI treatment than WT/WT patients. Cancer 2012;3579–3586. © 2011 American Cancer Society.